Journal of Viral Hepatitis

Article	Citations
Issue Information	154
Issue Information	36
	27
Issue Information	25
Baseline Alpha‐Fetoprotein Elevation and the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B: A Multicentre Cohort Study	25
Clinical Observational Study on HBV Reactivation After Direct‐Acting Antiviral Therapy in HCV /	24
Persistence of immunity against hepatitis A in Brazilian children vaccinated with a single dose of inactivated virus vaccine	24
International disease burden of acute viral hepatitis among adolescents and young adults: An observational study	23
The role of serum sphingolipids as potential biomarkers of non‐response to direct acting antiviral therapy in chronic hepatitis C virus infection	23
Uptake of the Birth Dose HBV Vaccine and Associated Factors Among Children in Sub‐Saharan Africa: An Analysis Using Recent Demographic and Health Survey Data	22
Hepatitis A occurrence and outbreaks in Europe over the past two decades: A systematic review	21
Hepatitis B Surface Antigen Loss and Improved Clinical Outcomes in US Individuals With Chronic Hepatitis B Virus Infection	20
Falling treatment uptake in the hepatitis C care cascade is a growing threat to achieving elimination	20
Hepatitis E Infection in Immunocompromised Patients Previously Treated With Rituximab	19
Investigating rates and risk factors for hepatitis C virus reinfection in people receiving antiviral treatment in England	19
Trends and Socio‐Demographic Patterns of Hepatitis B Virus Hospitalisations in Poland: A 12‐Year Nationwide Analysis	18
Early virologic relapse predicts alanine aminotransferase flares after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B	18
Issue Information	18
A cross‐sectional study of hepatitis C prevalence and correlates among persons who inject drugs in rural and non‐rural communities	18
Prevention of HBV Mother‐To‐Child Transmission ( MTCT ) Using Targeted HB	18
Long‐Term Follow‐Up of Neuropsychiatric Symptoms After Sustained Virological Response to Interferon‐Free and Interferon‐Based Hepatitis C Virus Treatment	17
A Network Map of Intracellular Alpha‐Fetoprotein Signalling in Hepatocellular Carcinoma	17
Evaluation of Blood Droplet Volumes on the Cobas Plasma Separation Card for HCV RNA Testing in Resource‐Limited Settings	16
Contribution of alcohol use in HIV/hepatitis C virus co‐infection to all‐cause and cause‐specific mortality: A collaboration of cohort studies	16
Integration and the risk of liver cancer—Is there a real risk?	15

Sex‐related difference analyses of efficacy and safety in clinical trials of direct‐acting antivirals to treat chronic HCV genotype 1 and 3 infections	15
Elevation of S2‐bound α1‐acid glycoprotein is associated with chronic hepatitis C virus infection and hepatocellular carcinoma	15
Characterisation of People Living With Chronic Hepatitis B Virus Infection in England and Stratification by HBsAg Levels: A Cross‐Sectional Study	15
Prevalence of Hepatitis B Among Migrants Living in High‐Income Countries With Low/Intermediate HBV Prevalence–A Systematic Review and Meta‐Analysis	15
Infectivity of Hepatitis B Virus Surface Antigen‐Positive Plasma With Undetectable HBV‐DNA: Can HBsAg Screening Be Discontinued in Egyptian Blood Donors?	15
Integrated Studies of Infectious Disease Elimination ( InSIDE ): Hepatitis C Antibody and RNA Stat	13
Issue Information	13
Issue Information	13
The changing epidemiology of delta hepatitis in Türkiye over three decades: A systematic review	13
Systematic Screening for Hepatitis B, C, and HIV and Linkage to Care in Patients With Mental Health Disorders Admitted to the Emergency Department	13
	12
Challenges of an EMR‐Based Hospital Alert Program for Micro‐Elimination of Hepatitis C in Tertiary Referral Hospitals	12
HCV hotline facilitates Hepatitis C elimination during the COVID‐19 pandemic	12
Outcomes and Survival of Egyptian Patients With Hepatitis B–Related Hepatocellular Carcinoma: A Multicentre Retrospective Study	12
Network‐basedstrategies to combatHCV: Examining social and spatial drivers of transmission amongPWIDin New Delhi	12
A declaration from people living with hepatitis B: A call for a whole person approach	11
Tenofovir versus entecavir for tertiary prevention of hepatocellular carcinoma in chronic hepatitis B infection after curative therapy: A systematic review and meta‐analysis	11
Universal HCV Screening in Hospitalised Patients in France: It Could Be a Good Option! The DEVICHO	11
The role of treatment of hepatitis C with direct‐acting antiviral agents on glycaemic control in diabetic patients: An updated systematic review and meta‐analysis	11
Hepatitis E prevalence and infection in solid‐organ transplant recipients in the United States	11
Safe co‐administration of direct‐acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: An international multicenter retrospective cohort study	11
	11
Challenges of hepatitis B treatment in rural Sub‐Saharan Africa: Treatment initiation and outcomes from a public hospital‐based clinic in Kono, Sierra Leone	11
Interventions to Increase Hepatitis B Testing Uptake Amongst Detained Populations: A Systematic Review	11
Epidemiological Burden of Hepatitis Delta Virus in the United States	10
Baseline and on‐treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals	10
Clinical and histological features of patients with chronic hepatitis B virus infection in the grey zone	10
Serum HBV RNA is associated with liver fibrosis regression in HBeAg‐positive chronic hepatitis B patients treated with nucleos(t)ide analogues	10
Measuring stigma associated with hepatitis B virus infection in Sierra Leone: Validation of an abridged Berger HIV stigma scale	10
Risk of drug‐induced liver injury in chronic hepatitis B and tuberculosis co‐infection: A systematic review and meta‐analysis	9
	9
The Efficacy and Sustainability of an Implementation Intervention ( FOCUS Program) on Linkage to Hepatitis C Care Time at a Community Health Center i	9
Duration of Nucleos(t)ide Analogue Treatments in Patients With Chronic Hepatitis B Virus Infection in the United States	9
Strategies to increase primary care provider capacity for hepatitis C care: The California ECHO‐PLUS study	9
Hepatitis D virus infection: Progress on the path toward disease control and cure	9
Associations Between Prior and Current Unhealthy Alcohol Use and Liver Morbidity Risk and Mortality Among Veterans With a History of Hepatitis C Who Have Achieved Sustained Virological Response	9
An updated assessment of hepatitis delta prevalence among adults in Canada: A meta‐analysis	9
Epidemiology and Outcomes of Hepatitis E Virus‐Associated Hospitalisations in the United States With a Focus on Pregnancy: A Nationwide Population Study, 1998–2020	9
Hepatitis B Vaccination Uptake and Associated Factors in the United States Before Implementing Universal Vaccination: A Nationally‐Representative Study	9
Performance of HCV core antigen and PCR testing in a predominantly genotype 3 population	8
Does hepatitis delta virus have a preference for hepatitis B virus genotype? A systematic review of the literature	8
Mixed‐Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis	8
Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi‐ethnic population: Universal screening is more comprehensive	8
Dynamic personalized prediction of the individual liver‐related risk after sustained viral response in HCV patients	8
Frequency, Severity and Impact of Pegylated Interferon Alpha–Associated Flares in Hepatitis D Infection	8
CHB patients with rtA181T‐mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes	8
Prognostic value of genotyping in hepatocellular carcinoma: A systematic review	8
The immune landscape in hepatitis delta virus infection—Still an open field	8
Clinical and patient‐reported outcome profile of patients with hepatitis B viral infection from the Global Liver Registry™	8
Socioeconomic Deprivation Weighs Heavily on Liver Fibrosis and Mortality After Hepatitis C Cure (ANRS CO22 Hepather)	8

Impact of hepatitis C treatment status on risk of Parkinson's disease and secondary parkinsonism in the era of direct‐acting antivirals	7
Performance Evaluation of the Elecsys HCV Duo Immunoassay in the Public Healthcare Setting in Cape Town, South Africa	7
A novel test and treat program for hepatitis C virus infection utilizing HCV core antigen testing, among police and general population, Islamabad, Pakistan, 2022	7
Preferences and feasibility of long‐acting technologies for treatment of hepatitis C virus in low‐ and middle‐income countries: A survey of providers and policymakers	7
MELD score < 18 rule out 28‐day ACLF development among inpatients with hepatitis B‐related previous compensated liver disease	7
Novel concepts on mechanisms underlying Hepatitis Delta virus persistence and related pathogenesis	7
Outcomes of Assisted Reproductive Technology in Women With Hepatitis B Infection	7
Knowledge and Perceptions of Hepatitis B in Immigrant Populations: A Systematic Review and Thematic Synthesis of Qualitative Research	7
Issue Information	7
Hepatitis Delta Coinfection Rates and All‐Cause Mortality Among Hepatitis B‐Infected Veterans in the USA	7
Issue Information	7
	7
A Qualitative Systematic Review of Barriers and Facilitators to Hepatitis B and C Programmes in Prisons	7
	7
Phase 1 study of safety and tolerability of an oral contraceptive containing low‐dose ethinyl oestradiol combined with glecaprevir/pibrentasvir treatment in healthy premenopausal women	7
Role of hepatitis B surface antibody in seroreversion of hepatitis B surface antigen in patients achieving hepatitis B surface antigen loss with pegylated interferon‐based therapy	7
Differing Epidemiology of Chronic Hepatitis C Infection, Treatment, and Outcomes Among Migrants and Australian‐Born Patients	7
Balancing Efficiency and Accuracy in Hepatitis C Rapid Antibody Testing: Insights From a Cluster Randomised Crossover Trial	7
Mortality and morbidity related to hepatitis C virus infection in hospitalized adults—A propensity score matched analysis	7
Kinetics changes in total cholesterol predict HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon‐alfa	7
	7
Screening rates for hepatitis B and C among low‐income US veterans: Data from the National Veteran Homeless and Other Poverty Experiences Study	7
Hepatocytes and Hepatic Stellate Cells Carry Different Levels of DNA Damage due to Their Sensitivity to Oxidative Stress in Chronic Hepatitis B	7
The Impact of Ambient Temperature on HCC Risk in Patients With Chronic Hepatitis B	7
Barriers and enablers to people‐centred viral hepatitis care in Vietnam and the Philippines: Results of a patient journey mapping study	7
Substance use and CD4/CD8 ratio in HIV/HCV co‐infected people receiving direct‐acting antiviral treatment (ANRS CO13 HEPAVIH)	6
MiRNome Profiling of Circulating Extracellular Vesicles in Patients With Chronic Hepatitis D Undergoing Pegylated Interferon Alpha Treatment	6
Identifying and Linking to Care and Treatment Persons With Hepatitis C Who Were Lost to Follow‐Up, Georgia 2023–2024	6
Early clinical efficacy of pegylated interferon treatment in patients with different phases of chronic HBV infection: A real‐world analysis	6
Sequence characterization of extracellular HBV RNA in patient plasma	6
Screening, Prevalence and Management of Chronic Viral Hepatitis C in Mental Health Setting: Towards the Eradication of A Forgotten Reservoir	6
Reply to ‘Assessing the hepatitis C epidemiology in Switzerland: It’s not that trivial’	6
Prevalence of and Risk Factors for Liver Enzyme Elevation After Hepatitis C Virologic Cure	6
Issue Information	6
Cigarette Smoking Is Associated With Lower Chance of Hepatitis B Surface Antigen Seroclearance and Altered Host Immunity	6
	6
Prevalence of hepatitis B virus (HBV) and latent tuberculosis co‐infection and risk of drug‐induced liver injury across two large HBV cohorts in the United	6
Recognisable Alcohol Use Significantly Increases the Risk of Adverse Outcomes in Patients With Hepatitis B Virus‐Related Cirrhosis	6
The Delta Delta: Gaps in screening and patient assessment for hepatitis D virus infection	6
Severe acute hepatitis of unknown origin in children: Is it still a mystery? What role does adenovirus play?	6
Comments on “Hepatitis B Virus ( HBV ) Treatment Eligibility in the UK : Retrospective Longitudina	6
Association Between Indirect Bilirubin Percentage to Albumin Ratio and Outcome of Hepatitis B Related Acute on Chronic Liver Failure Treated With Artificial Liver Support System	6
	6
A Programme of Hepatitis C Surveillance With Active Linkage to Care (HEAL) for Inpatients in Two Tertiary Hospitals in Jiangsu, China	6
Persistence of antibodies 5 years after hepatitis B vaccination in preterm birth children: A retrospective cohort study using real‐world data	5
Telemedicine for Low‐Barrier Hepatitis C Care in Rural Patients With Substance Use Disorders: Lessons From Taiwan	5
Genetic substructure and host‐specific natural selection trend across vaccine‐candidate ORF‐2 capsid protein of hepatitis‐E virus	5
Long‐Term Persistence of Hepatitis A Virus Immunity in Healthcare Workers Upto 25 Years After Vaccination	5
Impact of Universal Screening for HDV in HBV‐ Infected Patients on Chronic	5
Impact of treatment with direct‐acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co‐infected individuals	5
Shear wave elastography: How well does it perform in chronic hepatitis D virus infection?	5
Time to Hepatitis C Care Engagement and Treatment Outcomes in Canadian Immigrants Have Markedly Improved Over Three Decades	5
Prevalence and Factors Associated With Hepatitis B Virus Infection in Tigray Region, Northern Ethiopia	5
Changes in Serum Rheumatoid Factor Following Eradication of Hepatitis C Virus Infection With Interferon or Direct Antiviral Therapy	5
Hepatic Steatosis Inhibits Hepatitis B Virus Replication by Promoting miR ‐122‐5p‐ SOX4	5
Chronic viral hepatitis C micro‐elimination program using telemedicine in Guigang city	5
Lower Serum Albumin Level: A Prospective Risk Predictor of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection	5
Testing to sustain hepatitis C elimination targets in people who inject drugs: A network‐based model	5
Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days	5
Prevalence and determinants of hepatitis delta virus infection among HIV/hepatitis B‐coinfected adults in care in the United States	5
Thrombospondin 2 as a Predictive Biomarker for HCC in Hepatitis C Patients: A Longitudinal Study Following DAA Therapy	5
Hepatitis C prevalence and elimination planning in Pakistan, a bottom‐up approach accounting for provincial variation	5
Depletion of circ_0088046 suppressed cell growth and motility of hepatocellular carcinoma via circ_0088046‐miR‐1299‐RTKN2 ceRNA pathway	5
	5
Outcomes of a 1‐Year Pilot Study Implementing Universal Hepatitis Delta Virus Testing Among Veterans With Chronic Hepatitis B	5
Prevalence of hepatitis C among pregnant women in an Appalachian population	5
Hepatitis after gene therapy, what are the possible causes?	5
Substance use and CD4/CD8 ratio in HIV/HCV co‐infected people receiving direct‐acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply	5
Issue Information	5
Protective Role of Coffee in Chronic Liver Disease: A Focus on Processing	4
	4
Dynamic Changes in ELF Score Predict Hepatocellular Carcinoma in Chronic Hepatitis B Patients Receiving Antiviral Treatment	4
Cost‐Effectiveness of De Novo Combination of Tenofovir Alafenamide Fumarate and Peginterferon Alfa‐2b Versus Peginterferon Alfa‐2b Monotherapy of HBeAg	4
Modelling the potential impact of global hepatitis B vaccination on the burden of chronic hepatitis B in the United States	4
Efficacy and safety of pan‐genotypic sofosbuvir and velpatasvir in patients with hepatitis C and HIV coinfection on dolutegravir‐based antiretroviral therapy	4
Demographic and Clinical Characteristics of Patients With Hepatitis C and Hepatitis B Co‐Infection, Georgia, 2017–2023	4
Hepatitis C epidemiology and treatment outcomes in Italy: Impact of the DAA era and the COVID‐19 pandemic	4
	4
Test characteristics for combining non‐invasive liver fibrosis staging modalities in individuals with Hepatitis C virus	4
Issue Information	4

Trends in Use of Direct‐Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016–2024	4
Impact of Non‐Alcoholic Fatty Liver Disease on the HBsAg Loss of Patients With Chronic Hepatitis B Treated in Pegylated Interferon Alpha	4
Factors influencing compliance with Hepatitis C treatment in patients transitioning from prison to community—A summary scoping review	4
Reply to: ‘Abnormal liver function tests and coronavirus disease 2019: A close relationship’	4
A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI‐2173 in patients with chronic hepatitis B virus infection	4
Bulevirtide Monotherapy or in Combination for Chronic Hepatitis Delta: 2025 Update	4
Regarding the predictive role of CXCL16 in liver inflammation in chronic hepatitis B patients	4
Assessing the hepatitis C epidemiology in Switzerland: It’s not that trivial	4
Absence of Detectable Anti‐ HDV Antibodies Among HBsAg ‐Positive Blood Donors,	4
	4
The Silent Burden of Hepatitis B‐Related Stigma	4
Hepatitis C active viremia over time in an ED‐based testing programme: Impact, disparities and surveillance tool	4
HERACLIS_BLV_D: Adherence to Real‐Life Therapy With Bulevirtide in Chronic Hepatitis D	4